sorafenib + gemcitabine + cisplatin

**sorafenib + gemcitabine + cisplatin** is a **pharmaceutical combination regimen** of three drugs used as systemic therapy in oncology. Sorafenib is a multikinase inhibitor targeting tumor cell proliferation and angiogenesis, gemcitabine is a nucleoside analog inhibiting DNA synthesis, and cisplatin is a platinum-based DNA crosslinker causing apoptosis. This combination is primarily deployed in clinical trials for advanced solid tumors, notably **biliary tract adenocarcinoma**[1], **collecting duct carcinoma of the kidney**[3][5], and has been trialed in **non-small cell lung cancer**[2] and **hepatocellular carcinoma**[4]. The regimen is investigational and not standard of care; dosing and tolerability require adjustment due to overlapping hematologic and organ toxicities[1][3].

Brand names

GemzarPlatinolNexavar

Other names

GC plus sorafenib